{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:37:32Z","timestamp":1777613852744,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.rmed.2022.107093","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T07:32:53Z","timestamp":1671521573000},"page":"107093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions"],"prefix":"10.1016","volume":"206","author":[{"given":"Melissa","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-0976","authenticated-orcid":false,"given":"Kaitlin","family":"Sparrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5704-9380","authenticated-orcid":false,"given":"Chrystal","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Gillson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Stollery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.rmed.2022.107093_bib1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/resp.12496","article-title":"Clinical features and survival of lung cancer patients with pleural effusions","volume":"20","author":"Porcel","year":"2015","journal-title":"Respirol Carlton Vic"},{"issue":"5","key":"10.1016\/j.rmed.2022.107093_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0002-9343(77)90154-1","article-title":"Carcinomatous involvement of the pleura: an analysis of 96 patients","volume":"63","author":"Chernow","year":"1977","journal-title":"Am. J. Med."},{"issue":"6","key":"10.1016\/j.rmed.2022.107093_bib3","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/archinte.1987.00370060129021","article-title":"Malignant pleural effusions. A clinical cytopathologic study","volume":"147","author":"Irani","year":"1987","journal-title":"Arch. Intern. Med."},{"issue":"10","key":"10.1016\/j.rmed.2022.107093_bib4","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1097\/JTO.0b013e318267223a","article-title":"Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non\u2013small-cell lung cancer","volume":"7","author":"Morgensztern","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.rmed.2022.107093_bib5","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/crj.12292","article-title":"Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions: malignant pleural effusions in lung cancer","volume":"10","author":"Kasapoglu","year":"2016","journal-title":"Clin. Res. J"},{"issue":"1","key":"10.1016\/j.rmed.2022.107093_bib6","first-page":"47","article-title":"Prognostic value of pleural effusion in patients with non-small cell lung cancer","volume":"3","author":"Sugiura","year":"1997","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.rmed.2022.107093_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2007.03.004","article-title":"Pleural effusion in patients with non-small cell carcinoma--stage IV and not T4","volume":"57","author":"Alon","year":"2007","journal-title":"Lung Cancer Amst Neth"},{"issue":"7","key":"10.1016\/j.rmed.2022.107093_bib8","first-page":"593","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer","volume":"2","author":"Rami-Porta","year":"2007","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"6","key":"10.1016\/j.rmed.2022.107093_bib9","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1183\/09031936.00069812","article-title":"Survival of lung adenocarcinoma patients with malignant pleural effusion","volume":"41","author":"Wu","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2022.107093_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1378\/chest.117.1.73","article-title":"Predicting survival in patients with recurrent symptomatic malignant pleural effusions","volume":"117","author":"Burrows","year":"2000","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2022.107093_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12890-015-0025-z","article-title":"Important prognostic factors for survival in patients with malignant pleural effusion","volume":"15","author":"Zamboni","year":"2015","journal-title":"BMC Pulm. Med."},{"issue":"10","key":"10.1016\/j.rmed.2022.107093_bib12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.rmed.2022.107093_bib13","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.rmed.2022.107093_bib14","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.rmed.2022.107093_bib15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced Nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2022.107093_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.rmed.2022.107093_bib17","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2022.107093_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11606-010-1472-0","article-title":"Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review","volume":"26","author":"Van Meter","year":"2011","journal-title":"J. Gen. Intern. Med."},{"issue":"2","key":"10.1016\/j.rmed.2022.107093_bib19","doi-asserted-by":"crossref","first-page":"E235","DOI":"10.9778\/cmajo.20170163","article-title":"Clinical predictors of successful and earlier pleurodesis with a tunnelled pleural catheter in malignant pleural effusion: a cohort study","volume":"6","author":"Li","year":"2018","journal-title":"CMAJ Open"},{"issue":"2","key":"10.1016\/j.rmed.2022.107093_bib20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/LBR.0000000000000632","article-title":"Predictors of indwelling pleural catheter removal and infection: a single-center experience with 336 procedures","volume":"27","author":"Porcel","year":"2020","journal-title":"J Bronchol Interv Pulmonol"},{"issue":"1","key":"10.1016\/j.rmed.2022.107093_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejcts.2007.10.002","article-title":"Identification of clinical factors predicting Pleurx catheter removal in patients treated for malignant pleural effusion","volume":"33","author":"Warren","year":"2008","journal-title":"Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg."},{"issue":"4","key":"10.1016\/j.rmed.2022.107093_bib22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1378\/chest.13-2481","article-title":"Comparing cost of indwelling pleural catheter vs talc pleurodesis for malignant pleural effusion","volume":"146","author":"Penz","year":"2014","journal-title":"Chest"},{"issue":"13","key":"10.1016\/j.rmed.2022.107093_bib23","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2005.05.153","article-title":"Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial","volume":"23","author":"Cella","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.rmed.2022.107093_bib24","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1097\/JTO.0b013e31822adaf7","article-title":"Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)","volume":"6","author":"Thongprasert","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.rmed.2022.107093_bib25","first-page":"3279","article-title":"Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation","volume":"33","author":"Imai","year":"2013","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.rmed.2022.107093_bib26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/JTO.0000000000000053","article-title":"Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation\u2013positive non\u2013small-cell lung cancer treated with gefitinib or erlotinib","volume":"9","author":"Takeda","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.rmed.2022.107093_bib27","doi-asserted-by":"crossref","first-page":"908","DOI":"10.4143\/crt.2017.378","article-title":"EGFR mutation status in lung adenocarcinoma-associated malignant pleural effusion and efficacy of EGFR tyrosine kinase inhibitors","volume":"50","author":"Yang","year":"2018","journal-title":"Cancer Res Treat"},{"issue":"28","key":"10.1016\/j.rmed.2022.107093_bib28","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2012small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.rmed.2022.107093_bib29","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early assessment of lung cancer immunotherapy response via circulating tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"34","key":"10.1016\/j.rmed.2022.107093_bib30","doi-asserted-by":"crossref","first-page":"57826","DOI":"10.18632\/oncotarget.18406","article-title":"The efficacy of anti-PD-1\/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer","volume":"8","author":"Sheng","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.rmed.2022.107093_bib31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/icb.2016.126","article-title":"Targeting cancer-related inflammation in the era of immunotherapy","volume":"95","author":"Nakamura","year":"2017","journal-title":"Immunol. Cell Biol."},{"issue":"140","key":"10.1016\/j.rmed.2022.107093_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1183\/16000617.0019-2016","article-title":"Malignant pleural effusion: from bench to bedside","volume":"25","author":"Psallidas","year":"2016","journal-title":"Eur Respir Rev Off J Eur Respir Soc"},{"issue":"1","key":"10.1016\/j.rmed.2022.107093_bib33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s40425-019-0643-8","article-title":"Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors","volume":"7","author":"Ayeni","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.rmed.2022.107093_bib34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.rmed.2022.107093_bib35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2022.107093_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1554969","article-title":"Making cold malignant pleural effusions hot: driving novel immunotherapies","volume":"8","author":"Murthy","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.rmed.2022.107093_bib37","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/1471-2407-13-324","article-title":"Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid","volume":"13","author":"Scherpereel","year":"2013","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.rmed.2022.107093_bib38","first-page":"765","article-title":"The PD-L1\/PD-1 pathway promotes dysfunction, but not \u201cexhaustion\u201d","volume":"66","author":"Prado-Garcia","year":"2017","journal-title":"in tumor-responding T cells from pleural effusions in lung cancer patients. Cancer Immunol Immunother CII"},{"issue":"1","key":"10.1016\/j.rmed.2022.107093_bib39","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.12845","article-title":"Interleukin-2 reverses CD8+ T cell exhaustion in clinical malignant pleural effusion of lung cancer","volume":"186","author":"Hu","year":"2016","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.rmed.2022.107093_bib40","first-page":"203","article-title":"Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?","volume":"14","author":"Radosavljevic","year":"2009","journal-title":"J BUON Off J Balk Union Oncol"},{"issue":"8","key":"10.1016\/j.rmed.2022.107093_bib41","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1164\/rccm.201607-1404OC","article-title":"Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions. The ASAP trial","volume":"195","author":"Wahidi","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611122003584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611122003584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T19:05:11Z","timestamp":1735758311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611122003584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":41,"alternative-id":["S0954611122003584"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2022.107093","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2022.107093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107093"}}